XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice
Source: SeekingAlpha
2025-12-24 16:33:19 ET
More on XTL Biopharmaceuticals
- Seeking Alpha’s Quant Rating on XTL Biopharmaceuticals
- Financial information for XTL Biopharmaceuticals
Read the full article on Seeking Alpha
For further details see:
XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice
XTL Biopharmaceuticals Ltd.
NASDAQ: XTLB
XTLB Trading
2.84% G/L:
$0.6523 Last:
297 Volume:
$0.6523 Open:
XTLB Latest News
February 27, 2026 04:30:00 pm
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
January 23, 2026 04:10:00 pm
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
January 13, 2026 09:38:22 am
Morning Market Brief: From IP Land Grabs to FDA Greenlights, Small-Cap Innovation Takes Center Stage
XTLB Stock Data
$2,098,137
1,046,204
N/A
8
N/A
Biotechnology & Life Sciences
Healthcare
IL
Ramat Gan
